Émilie Bortolussi-Courval
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Émilie Bortolussi-Courval has a total of 69 co-authors. Here are the top co-authors by number of shared publications:
- Emily Gibson McDonald
Division of Experimental Medicine, Department of Medicine, McGill University , Montreal, Quebec
13 shared publications - Todd Campbell Lee
Division of Infectious Diseases, Department of Medicine, McGill University , Montreal, Quebec
12 shared publications Jimin J. Lee
Division of Experimental Medicine, Faculty of Medicine and Health Sciences McGill University Montréal Quebec Canada
3 shared publicationsRyan Hanula
Division of Experimental Medicine, Faculty of Medicine and Health Sciences, McGill University, Montréal, Québec, Canada
3 shared publicationsSydney B. Ross
Faculty of Medicine and Health Sciences McGill University Montreal Quebec Canada
3 shared publicationsTodd C. Lee
McGill University Faculty of Medicine and Health Sciences
3 shared publications
Latest Publications
- Open Access
- 7 May 2026
- Published by Wiley in Journal of the American Geriatrics Society
- Vol. 74 (8) , 2473-2479
Measuring Medication Related Harm: Proposed Guidance for Adverse Drug Event Adjudication to Harmonize Outcomes in Deprescribing Research
- 7 May 2026
- Published by Wiley in Journal of the American Geriatrics Society
- Vol. 74 (8) , 2473-2479
Open AccessMeasuring Medication Related Harm: Proposed Guidance for Adverse Drug Event Adjudication to Harmonize Outcomes in Deprescribing Research
- Open Access
- 24 April 2025
- Published by Oxford University Press (OUP) in Open Forum Infectious Diseases
- Vol. 12 (5) , ofaf248
Global Practice Variation in the Management of Clostridioides difficile Infections: An International Cross-Sectional Survey of Clinicians
Background: Clostridioides difficile infections (CDIs) are associated with significant morbidity, mortality, and economic burden globally. International guidelines conflict on various aspects of management, so we conducted a clinician survey to evaluate global practice variability on CDI diagnosis, treatment, and prophylaxis to inform future clinical trials. Methods: An anonymous online survey through REDCap was distributed through multiple channels. Attending physicians, infectious disease pharmacists, and fellows in infectious diseases or medical microbiology who had managed ≥3 cases of CDI in the preceding year were eligible. Responses were compared across continents by chi-square test. Results: Three hundred fifty-nine survey responses were collected from 31 countries and 6 continents (North America 80.5%, Europe 11.7%, other continents 7.8%). A 2-step CDI diagnostic algorithm was used by 75.8% of respondents with heterogeneity in assay type. Similarly, there was significant variability in first-line agents for the treatment of first episodes and first recurrences of uncomplicated CDI and a lack of consensus on treatments for fulminant CDI. Secondary CDI prophylaxis during antibiotic re-exposure was most commonly used in North America (84.1%), followed by other continents (50.0%) and Europe (31.0%; P < .001). Oral vancomycin was the most frequently used agent (96.3%), with significant variability in the dose (125–500 mg daily) and duration (1–28 days; P < .01). Conclusions: Substantial global variability exists with respect to CDI diagnosis, treatment, and secondary prophylaxis, likely due to divergent guidelines and a paucity of robust evidence. These findings highlight critical knowledge gaps and areas of clinical equipoise and underscore the need for further randomized controlled trials to establish harmonized international best practices for CDI.
- 24 April 2025
- Published by Oxford University Press (OUP) in Open Forum Infectious Diseases
- Vol. 12 (5) , ofaf248
Open AccessGlobal Practice Variation in the Management of Clostridioides difficile Infections: An International Cross-Sectional Survey of Clinicians
Background: Clostridioides difficile infections (CDIs) are associated with significant morbidity, mortality, and economic burden globally. International guidelines conflict on various aspects of management, so we conducted a clinician survey to evaluate global practice variability on CDI diagnosis, treatment, and prophylaxis to inform future clinical trials. Methods: An anonymous online survey through REDCap was distributed through multiple channels. Attending physicians, infectious disease pharmacists, and fellows in infectious diseases or medical microbiology who had managed ≥3 cases of CDI in the preceding year were eligible. Responses were compared across continents by chi-square test. Results: Three hundred fifty-nine survey responses were collected from 31 countries and 6 continents (North America 80.5%, Europe 11.7%, other continents 7.8%). A 2-step CDI diagnostic algorithm was used by 75.8% of respondents with heterogeneity in assay type. Similarly, there was significant variability in first-line agents for the treatment of first episodes and first recurrences of uncomplicated CDI and a lack of consensus on treatments for fulminant CDI. Secondary CDI prophylaxis during antibiotic re-exposure was most commonly used in North America (84.1%), followed by other continents (50.0%) and Europe (31.0%; P < .001). Oral vancomycin was the most frequently used agent (96.3%), with significant variability in the dose (125–500 mg daily) and duration (1–28 days; P < .01). Conclusions: Substantial global variability exists with respect to CDI diagnosis, treatment, and secondary prophylaxis, likely due to divergent guidelines and a paucity of robust evidence. These findings highlight critical knowledge gaps and areas of clinical equipoise and underscore the need for further randomized controlled trials to establish harmonized international best practices for CDI.
- Open Access
- 28 March 2025
- Published by Wiley in Journal of the American Geriatrics Society
- Vol. 73 (6) , 1918-1928
Criteria to Report Adverse Drug Withdrawal Events in Clinical Trials: A Systematic Review
Background: Polypharmacy is a major risk factor for adverse drug events (ADEs), which are a common cause of hospitalization, especially among older adults. Deprescribing is a promising strategy to prevent ADEs; however, clinicians may hesitate to deprescribe for fear of causing adverse drug withdrawal events (ADWEs). Collectively, ADWEs are the re‐emergence of symptoms or a disease state due to the discontinuation of a medication. Although capturing ADWEs is critical to understanding the complications that might arise from deprescribing, these events may not be routinely or systematically captured in clinical trials. Objectives: We aimed to determine the frequency of ADWE reporting, compare the strengths and limitations of different approaches, and compare the rates of the number of ADWEs detected across trials. Methods: A systematic review was performed following the Preferred Reporting Items for Systematic Reviews and Meta‐Analyses checklist. The search strategy was developed with a research librarian, and studies were identified using Ovid Medline, Embase, and the Cochrane Central Register of Controlled Trials from inception to July 2, 2024. We included all randomized controlled trials testing a deprescribing intervention in older adults (mean or median age ≥ 65 years) and analyzed a subsample of the studies reporting ADWEs as an outcome. Results: Among the 139 eligible studies that were identified, only 12 reported an ADWE. These studies utilized 6 approaches to capture ADWEs: Naranjo ADWE Probability Scale; clinical monitoring for specific withdrawal symptoms; identification through ICD‐10 codes; identification of ADWEs as a subset of confirmed ADEs; patient/caregiver self‐report; and clinical judgment. Conclusion: Results confirmed that few deprescribing studies capture ADWEs and there is a lack of standardized reporting. A harmonized approach to capturing ADWEs with specific criteria could ensure more consistent results in deprescribing trials, improve our understanding of this important outcome, and facilitate future meta‐analyses.
- 28 March 2025
- Published by Wiley in Journal of the American Geriatrics Society
- Vol. 73 (6) , 1918-1928
Open AccessCriteria to Report Adverse Drug Withdrawal Events in Clinical Trials: A Systematic Review
Background: Polypharmacy is a major risk factor for adverse drug events (ADEs), which are a common cause of hospitalization, especially among older adults. Deprescribing is a promising strategy to prevent ADEs; however, clinicians may hesitate to deprescribe for fear of causing adverse drug withdrawal events (ADWEs). Collectively, ADWEs are the re‐emergence of symptoms or a disease state due to the discontinuation of a medication. Although capturing ADWEs is critical to understanding the complications that might arise from deprescribing, these events may not be routinely or systematically captured in clinical trials. Objectives: We aimed to determine the frequency of ADWE reporting, compare the strengths and limitations of different approaches, and compare the rates of the number of ADWEs detected across trials. Methods: A systematic review was performed following the Preferred Reporting Items for Systematic Reviews and Meta‐Analyses checklist. The search strategy was developed with a research librarian, and studies were identified using Ovid Medline, Embase, and the Cochrane Central Register of Controlled Trials from inception to July 2, 2024. We included all randomized controlled trials testing a deprescribing intervention in older adults (mean or median age ≥ 65 years) and analyzed a subsample of the studies reporting ADWEs as an outcome. Results: Among the 139 eligible studies that were identified, only 12 reported an ADWE. These studies utilized 6 approaches to capture ADWEs: Naranjo ADWE Probability Scale; clinical monitoring for specific withdrawal symptoms; identification through ICD‐10 codes; identification of ADWEs as a subset of confirmed ADEs; patient/caregiver self‐report; and clinical judgment. Conclusion: Results confirmed that few deprescribing studies capture ADWEs and there is a lack of standardized reporting. A harmonized approach to capturing ADWEs with specific criteria could ensure more consistent results in deprescribing trials, improve our understanding of this important outcome, and facilitate future meta‐analyses.
- Open Access
- 23 March 2025
- Published by Wiley in Journal of the American Geriatrics Society
- Vol. 73 (6) , 1753-1761
Prescribing Patterns and Impact of Sedatives in Hospitalized Older Adults: A Secondary Analysis of the MedSafer Study
Background: We aimed to examine the impact of sedative prescription patterns in hospitalized older adults on post‐discharge adverse drug events (ADEs), falls, and sleep. Methods: We conducted a secondary analysis of the MedSafer randomized controlled trial (RCT; NCT03272607) which included hospitalized adults ≥ 65 years of age who were taking ≥ 5 medications. We identified patients who completed follow‐up at 30 days post‐discharge and provided patient‐reported outcomes for sleep disturbance (PROMIS SD 4a). We grouped patients based on sedative use as follows: nonusers, continued home use (pre‐ and post‐hospitalization), deprescribed home use, and new use at discharge. Using multivariable logistic regression, we compared the odds of patients having experienced ≥ 1 ADE (not necessarily ascribed to sedatives), a fall, or any adverse event within 30 days post‐discharge. We also used ordinal logistic regression and a minimal important difference approach to compare the change in sleep disturbance at 30 days post‐discharge. Results: The cohort comprised 3630 patients with a median age of 78. A total of 2810 (77.4%) were categorized as nonusers; 475 (13.1%) continued home use; 293 (8.1%) deprescribed home use; and 52 (1.4%) new users at discharge. Compared to the continued home use group, the deprescribed group was substantially less likely to experience an ADE post‐discharge (adjusted odds ratio [aOR], 0.39 [95% CI, 0.16–0.97]). Correspondingly, new users at discharge had substantially higher odds of falls (aOR, 2.51 [95% CI, 1.13–5.61]). Favorable changes in sleep disturbance were more likely among nonusers (aOR, 1.29 [95% CI, 1.05–1.58]) and deprescribed users (aOR, 1.11 [95% CI, 0.82–1.50]) when compared to continued users. Conclusions: In this cohort, patients who had their sedatives deprescribed were 61% less likely than continued users to have a post‐discharge ADE, and new sedative use at discharge was associated with appreciable risk of falls. Hospitalization likely represents a window of opportunity to improve care by promoting sedative deprescription and avoiding new starts.
- 23 March 2025
- Published by Wiley in Journal of the American Geriatrics Society
- Vol. 73 (6) , 1753-1761
Open AccessPrescribing Patterns and Impact of Sedatives in Hospitalized Older Adults: A Secondary Analysis of the MedSafer Study
Background: We aimed to examine the impact of sedative prescription patterns in hospitalized older adults on post‐discharge adverse drug events (ADEs), falls, and sleep. Methods: We conducted a secondary analysis of the MedSafer randomized controlled trial (RCT; NCT03272607) which included hospitalized adults ≥ 65 years of age who were taking ≥ 5 medications. We identified patients who completed follow‐up at 30 days post‐discharge and provided patient‐reported outcomes for sleep disturbance (PROMIS SD 4a). We grouped patients based on sedative use as follows: nonusers, continued home use (pre‐ and post‐hospitalization), deprescribed home use, and new use at discharge. Using multivariable logistic regression, we compared the odds of patients having experienced ≥ 1 ADE (not necessarily ascribed to sedatives), a fall, or any adverse event within 30 days post‐discharge. We also used ordinal logistic regression and a minimal important difference approach to compare the change in sleep disturbance at 30 days post‐discharge. Results: The cohort comprised 3630 patients with a median age of 78. A total of 2810 (77.4%) were categorized as nonusers; 475 (13.1%) continued home use; 293 (8.1%) deprescribed home use; and 52 (1.4%) new users at discharge. Compared to the continued home use group, the deprescribed group was substantially less likely to experience an ADE post‐discharge (adjusted odds ratio [aOR], 0.39 [95% CI, 0.16–0.97]). Correspondingly, new users at discharge had substantially higher odds of falls (aOR, 2.51 [95% CI, 1.13–5.61]). Favorable changes in sleep disturbance were more likely among nonusers (aOR, 1.29 [95% CI, 1.05–1.58]) and deprescribed users (aOR, 1.11 [95% CI, 0.82–1.50]) when compared to continued users. Conclusions: In this cohort, patients who had their sedatives deprescribed were 61% less likely than continued users to have a post‐discharge ADE, and new sedative use at discharge was associated with appreciable risk of falls. Hospitalization likely represents a window of opportunity to improve care by promoting sedative deprescription and avoiding new starts.
- Open Access
- 13 October 2024
- Published by Wiley in Basic & Clinical Pharmacology & Toxicology
- Vol. 135 (6) , 685-692
Efficacy of weekly versus daily cholecalciferol for repleting serum vitamin D (25(OH)D) deficiency: A systematic review and meta‐analysis of randomized controlled trials
Background/rationale: Weekly cholecalciferol can replace daily supplementation to reduce pill burden in patients with complex medication regimens and hypovitaminosis D, but evidence supporting this switch is unclear.Objective: We aimed to determine whether weekly cholecalciferol was superior to daily cholecalciferol to replete patients with hypovitaminosis D.Methods: We conducted a systematic review of randomized controlled trials involving participants with baseline hypovitaminosis D (versus daily cholecalciferol dosing and where serum cholecalciferol was measured within 120 days of starting treatment. We searched MEDLINE, CINAHL and EMBASE from inception to 7 May 2024. A random‐effects meta‐analysis evaluated the odds ratio for repletion of serum vitamin D levels.Findings: Eight trials involving 542 patients were included in the analysis. Weekly and daily cholecalciferol were not significantly different in correcting hypovitaminosis D (OR = 1.5, 95% CI = 0.3–6.9, p = 0.6, favouring weekly dosing, I2 = 85.3%). A sensitivity analysis excluding otherwise healthy patients had similar findings (OR = 0.8, 95% CI = 0.3–2.1, p = 0.6). Most studies were at risk of bias; the different doses being compared increased the heterogeneity.Conclusions: Limited direct evidence supports a switch from daily to weekly cholecalciferol dosing; however, weekly supplementation was not demonstrably worse at repleting levels and decreased a patient's daily pill burden.
- 13 October 2024
- Published by Wiley in Basic & Clinical Pharmacology & Toxicology
- Vol. 135 (6) , 685-692
Open AccessEfficacy of weekly versus daily cholecalciferol for repleting serum vitamin D (25(OH)D) deficiency: A systematic review and meta‐analysis of randomized controlled trials
Background/rationale: Weekly cholecalciferol can replace daily supplementation to reduce pill burden in patients with complex medication regimens and hypovitaminosis D, but evidence supporting this switch is unclear.Objective: We aimed to determine whether weekly cholecalciferol was superior to daily cholecalciferol to replete patients with hypovitaminosis D.Methods: We conducted a systematic review of randomized controlled trials involving participants with baseline hypovitaminosis D (versus daily cholecalciferol dosing and where serum cholecalciferol was measured within 120 days of starting treatment. We searched MEDLINE, CINAHL and EMBASE from inception to 7 May 2024. A random‐effects meta‐analysis evaluated the odds ratio for repletion of serum vitamin D levels.Findings: Eight trials involving 542 patients were included in the analysis. Weekly and daily cholecalciferol were not significantly different in correcting hypovitaminosis D (OR = 1.5, 95% CI = 0.3–6.9, p = 0.6, favouring weekly dosing, I2 = 85.3%). A sensitivity analysis excluding otherwise healthy patients had similar findings (OR = 0.8, 95% CI = 0.3–2.1, p = 0.6). Most studies were at risk of bias; the different doses being compared increased the heterogeneity.Conclusions: Limited direct evidence supports a switch from daily to weekly cholecalciferol dosing; however, weekly supplementation was not demonstrably worse at repleting levels and decreased a patient's daily pill burden.
- Open Access
- 27 September 2024
- Published by Taylor & Francis in Health Literacy and Communication Open
- Vol. 2 (1)
Use of MedSafer electronic decision support for deprescribing in patients on hemodialysis: a qualitative study
- 27 September 2024
- Published by Taylor & Francis in Health Literacy and Communication Open
- Vol. 2 (1)
Open AccessUse of MedSafer electronic decision support for deprescribing in patients on hemodialysis: a qualitative study
- Open Access
- 5 September 2024
- Published by Wiley in Journal of the American Geriatrics Society
- Vol. 73 (1) , 302-305
Deprescribing is associated with reduced readmission to hospital: An updated meta‐analysis of randomized controlled trials
See the related reply by Fontana et al . in this issue.
- 5 September 2024
- Published by Wiley in Journal of the American Geriatrics Society
- Vol. 73 (1) , 302-305
Open AccessDeprescribing is associated with reduced readmission to hospital: An updated meta‐analysis of randomized controlled trials
See the related reply by Fontana et al . in this issue.
- Open Access
- 5 September 2024
- Published by Wiley in Journal of the American Geriatrics Society
- Vol. 72 (11) , 3530-3540
The cost of potentially inappropriate medications for older adults in Canada: A comparative cross‐sectional study
Background: Potentially inappropriate medications (PIMs) are medications whereby the harms may outweigh the benefits for a given individual. Although overprescribed to older adults, their direct costs on the healthcare system are poorly described. Methods: This was a cross‐sectional study of the cost of PIMs for Canadians aged 65 and older, using adapted criteria from the American Geriatrics Society. We examined prescription claims information from the National Prescription Drug Utilization Information System in 2021 and compared these with 2013. The overall levels of inflation‐adjusted total annual expenditure on PIMs, average cost per quarterly exposure, and average quarterly exposures to PIMs were calculated in CAD$. Results: Exposure to most categories of PIMs decreased, aside from gabapentinoids, proton pump inhibitors, and antipsychotics, all of which increased. Canadians spent $1 billion on PIMs in 2021, a 33.6% reduction compared with 2013 ($1.5 billion). In 2021, the largest annual expenditures were on proton pump inhibitors ($211 million) and gabapentinoids ($126 million). The quarterly amount spent on PIMs per person exposed decreased from $95 to $57. In terms of mean cost per person, opioids and antipsychotics were highest ($138 and $118 per exposure). Some cost savings may have occurred secondary to an observed decline of 16.4% in the quarterly rate of exposure to PIMs (from 7301 per 10,000 in 2013 to 6106 per 10,000 in 2021). Conclusions: While expenditures on PIMs have declined in Canada, the overall cost remains high. Prescribing of some seriously harmful classes of PIMs has increased and so directed, scalable interventions are needed.
- 5 September 2024
- Published by Wiley in Journal of the American Geriatrics Society
- Vol. 72 (11) , 3530-3540
Open AccessThe cost of potentially inappropriate medications for older adults in Canada: A comparative cross‐sectional study
Background: Potentially inappropriate medications (PIMs) are medications whereby the harms may outweigh the benefits for a given individual. Although overprescribed to older adults, their direct costs on the healthcare system are poorly described. Methods: This was a cross‐sectional study of the cost of PIMs for Canadians aged 65 and older, using adapted criteria from the American Geriatrics Society. We examined prescription claims information from the National Prescription Drug Utilization Information System in 2021 and compared these with 2013. The overall levels of inflation‐adjusted total annual expenditure on PIMs, average cost per quarterly exposure, and average quarterly exposures to PIMs were calculated in CAD$. Results: Exposure to most categories of PIMs decreased, aside from gabapentinoids, proton pump inhibitors, and antipsychotics, all of which increased. Canadians spent $1 billion on PIMs in 2021, a 33.6% reduction compared with 2013 ($1.5 billion). In 2021, the largest annual expenditures were on proton pump inhibitors ($211 million) and gabapentinoids ($126 million). The quarterly amount spent on PIMs per person exposed decreased from $95 to $57. In terms of mean cost per person, opioids and antipsychotics were highest ($138 and $118 per exposure). Some cost savings may have occurred secondary to an observed decline of 16.4% in the quarterly rate of exposure to PIMs (from 7301 per 10,000 in 2013 to 6106 per 10,000 in 2021). Conclusions: While expenditures on PIMs have declined in Canada, the overall cost remains high. Prescribing of some seriously harmful classes of PIMs has increased and so directed, scalable interventions are needed.
- Open Access
- 31 August 2024
- Published by Wiley
Efficacy of Weekly versus Daily Cholecalciferol for Repleting Vitamin D (1,25-Dihydroxy Vitamin D) Deficiency: A Systematic Review and Meta-Analysis of Randomized Controlled Trials
Background/Rationale Weekly cholecalciferol can be an alternative to daily supplementation to reduce pill burden in patients with complex medication regimens and hypovitaminosis D, but evidence supporting this switch is unclear. Objective We aimed to determine whether weekly cholecalciferol was superior to daily cholecalciferol to replete patients with hypovitaminosis D. Methods We conducted a systematic review of randomized controlled trials involving participants with baseline hypovitaminosis D (th , 2024. A random-effects meta-analysis evaluated the odds ratio for repletion of serum Vitamin D levels. Findings Eight trials involving 542 patients were included in the analysis. Weekly D3 and daily cholecalciferol were not significantly different in correcting hypovitaminosis D (OR=1.5, 95% CI = 0.3-6.9, p=0.6, favoring weekly dosing, I 2 =85.3%). A sensitivity analysis excluding otherwise healthy patients had similar findings (OR=0.8, 95% CI=0.3–2.1, p=0.6). Most studies were judged to be at risk of bias, the different doses being compared increased the heterogeneity (I 2 =85.3%). Conclusions There is limited direct evidence supporting a switch from daily to weekly cholecalciferol dosing; however, weekly supplementation was not demonstrably worse at repleting levels and decreases a patient’s daily pill burden.
- 31 August 2024
- Published by Wiley
Open AccessEfficacy of Weekly versus Daily Cholecalciferol for Repleting Vitamin D (1,25-Dihydroxy Vitamin D) Deficiency: A Systematic Review and Meta-Analysis of Randomized Controlled Trials
Background/Rationale Weekly cholecalciferol can be an alternative to daily supplementation to reduce pill burden in patients with complex medication regimens and hypovitaminosis D, but evidence supporting this switch is unclear. Objective We aimed to determine whether weekly cholecalciferol was superior to daily cholecalciferol to replete patients with hypovitaminosis D. Methods We conducted a systematic review of randomized controlled trials involving participants with baseline hypovitaminosis D (th , 2024. A random-effects meta-analysis evaluated the odds ratio for repletion of serum Vitamin D levels. Findings Eight trials involving 542 patients were included in the analysis. Weekly D3 and daily cholecalciferol were not significantly different in correcting hypovitaminosis D (OR=1.5, 95% CI = 0.3-6.9, p=0.6, favoring weekly dosing, I 2 =85.3%). A sensitivity analysis excluding otherwise healthy patients had similar findings (OR=0.8, 95% CI=0.3–2.1, p=0.6). Most studies were judged to be at risk of bias, the different doses being compared increased the heterogeneity (I 2 =85.3%). Conclusions There is limited direct evidence supporting a switch from daily to weekly cholecalciferol dosing; however, weekly supplementation was not demonstrably worse at repleting levels and decreases a patient’s daily pill burden.
- Open Access
- 21 March 2024
- Published by Elsevier in Kidney Medicine
- Vol. 6 (5) , 100810
Medication Deprescribing in Patients Receiving Hemodialysis: A Prospective Controlled Quality Improvement Study
- 21 March 2024
- Published by Elsevier in Kidney Medicine
- Vol. 6 (5) , 100810
Open AccessMedication Deprescribing in Patients Receiving Hemodialysis: A Prospective Controlled Quality Improvement Study